Q4 2025 · 13F-HR
Defilade Capital Management, L.P.holdings as filed
Filed 2026-02-13 · accession 0002088557-26-000002
$737.7M
Reported value
33
Positions
2025-12-31
Period end
The Brief · Defilade Capital Management, L.P. · Q4 2025
AI · grounded in 13F
Defilade Capital Management, L.P. established a new position in PFE valued at $54.87M. The fund also initiated new stakes in ABBV for $52.02M and NVS for $50.02M. Additional new positions include ICUI at $48.61M and PACS at $43.98M. Total assets under management stand at $737.73M across 33 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 717081103 | PFE | PFIZER INC | $54.9M | 7.44% | 2,203,504 | Common | SOLE |
| 00287Y109 | ABBV | ABBVIE INC | $52.0M | 7.05% | 227,669 | Common | SOLE |
| 66987V109 | NVS | NOVARTIS AG | $50.0M | 6.78% | 362,816 | Common | SOLE |
| 44930G107 | ICUI | ICU MED INC | $48.6M | 6.59% | 340,745 | Common | SOLE |
| 69380Q107 | PACS | PACS GROUP INC | $44.0M | 5.96% | 1,145,485 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $34.3M | 4.65% | 31,950 | Common | SOLE |
| G8473T100 | STE | STERIS PLC | $34.3M | 4.65% | 135,307 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $30.9M | 4.18% | 1,234,634 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $28.9M | 3.92% | 363,454 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $28.5M | 3.86% | 161,992 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $27.1M | 3.67% | 269,043 | Common | SOLE |
| 46120E602 | ISRG | INTUITIVE SURGICAL INC | $25.9M | 3.51% | 45,662 | Common | SOLE |
| 806407102 | HSIC | HENRY SCHEIN INC | $24.2M | 3.28% | 320,422 | Common | SOLE |
| 379577208 | GMED | GLOBUS MED INC | $23.3M | 3.16% | 267,212 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $21.7M | 2.94% | 1,414,755 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $20.2M | 2.74% | 568,619 | Common | SOLE |
| 016255101 | ALGN | ALIGN TECHNOLOGY INC | $20.0M | 2.71% | 128,060 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $18.3M | 2.48% | 85,694 | Common | SOLE |
| 252131107 | DXCM | DEXCOM INC | $16.3M | 2.20% | 244,881 | Common | SOLE |
| 075887109 | BDX | BECTON DICKINSON & CO | $15.8M | 2.14% | 81,207 | Common | SOLE |
| 04963C209 | ATRC | ATRICURE INC | $15.7M | 2.13% | 397,636 | Common | SOLE |
| G5509L101 | LIVN | LIVANOVA PLC | $14.9M | 2.01% | 241,413 | Common | SOLE |
| 02081G201 | ATEC | ALPHATEC HLDGS INC | $13.2M | 1.79% | 626,754 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $10.8M | 1.47% | 656,713 | Common | SOLE |
| 377322102 | GKOS | GLAUKOS CORP | $10.4M | 1.40% | 91,703 | Common | SOLE |
| 78349D107 | RXST | RXSIGHT INC | $9.5M | 1.29% | 913,090 | Common | SOLE |
| 28414H103 | ELAN | ELANCO ANIMAL HEALTH INC | $9.1M | 1.23% | 401,283 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $8.7M | 1.18% | 50,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $8.3M | 1.12% | 681,663 | Common | SOLE |
| 879369106 | TFX | TELEFLEX INCORPORATED | $5.2M | 0.71% | 42,850 | Common | SOLE |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $5.0M | 0.67% | 3,290,450 | Common | SOLE |
| 207410101 | CNMD | CONMED CORP | $4.2M | 0.57% | 104,129 | Common | SOLE |
| 30054Y107 | EVMN | EVOMMUNE INC | $3.7M | 0.50% | 215,418 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.